Ad is loading...
CVMAX
Price
$17.33
Change
-$0.10 (-0.57%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

CVMAX vs RNWFX

Header iconCVMAX vs RNWFX Comparison
Open Charts CVMAX vs RNWFXBanner chart's image
Calvert Emerging Markets Equity A
Price$17.33
Change-$0.10 (-0.57%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
CVMAX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVMAX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVMAX is a Buy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. CVMAX (1.37B). RNWFX pays higher dividends than CVMAX: RNWFX (1.51) vs CVMAX (0.70). CVMAX was incepted earlier than RNWFX: CVMAX (12 years) vs RNWFX (23 years). CVMAX is a more actively managed with annual turnover of: 59.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than CVMAX: RNWFX (250) vs CVMAX (1000). RNWFX annual gain was more profitable for investors over the last year : 11.54 vs. CVMAX (10.64). RNWFX return over 5 years is better than : 17.17 vs. CVMAX (5.38).
CVMAXRNWFXCVMAX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years23 years-
Gain YTD7.1747.099101%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets1.37B60.9B2%
Annual Yield % from dividends0.701.5147%
Returns for 1 year10.6411.5492%
Returns for 3 years-18.11-14.55125%
Returns for 5 years5.3817.1731%
Returns for 10 years37.2641.0091%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics